Author

B. Gryder

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:cell signaling & trafficking· 2 Approach:experimental assay· 2 Approach:statistical model· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1

Frequent Co-Authors

J. Khan· 2 shared A. Grayson· 1 shared A. N. Alilin· 1 shared B. Capaldo· 1 shared C. Thiele· 1 shared D. Banerjee· 1 shared D. J. VanderWeele· 1 shared E. Y. Chen· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

J. Khan

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

SNAI2-mediated direct repression of BIM protects rhabdomyosarcoma from ionizing radiation

L. Wang, N. R. Hensch, K. Bondra, P. Sreenivas, X. R. Zhao, J. Chen, K. Baxi, R. M. Campos, B. Gryder, S. Pomella, R. Rota, E. Y. Chen, J. Khan, P. J. Houghton, M. S. Ignatius

This study identifies SNAI2 as a repressor of BIM, protecting rhabdomyosarcoma from ionizing radiation through a P53-independent mechanism.

bioRxiv · Jan 25, 2021Cancer Biology

Lineage specific transcription factor waves reprogram neuroblastoma from self-renewal to differentiation

D. Banerjee, B. Gryder, S. Bagchi, Z. Liu, H.-C. Chen, M. Xu, M. Sun, Z. Vaksman, S. J. Diskin, J. Khan, C. Thiele

This study identifies lineage-specific transcription factors and super-enhancers driving neuroblastoma self-renewal and differentiation using ATRA treatment and CRISPR screening.

bioRxiv · Jul 23, 2020Cancer Biology

Targeting the PI3K/AKT pathway overcomes enzalutamide resistance by inhibiting induction of the glucocorticoid receptor

R. M. Adelaiye-Ogala, B. Gryder, Y. T. M. Nguyen, A. N. Alilin, A. Grayson, K. H. Jansson, M. L. Beshiri, S. Agarwal, B. Capaldo, J. A. Rodriguez-Nieves, K. Kelly, D. J. VanderWeele

This study shows that inhibiting the PI3K/AKT pathway blocks GR induction and overcomes enzalutamide resistance in prostate cancer by remodeling chromatin and enhancing AR activity.

bioRxiv · Oct 1, 2019Cancer Biology